Learn more

LABORATORIO RAAM DE SAHUAYO S A DE C V

Overview
  • Total Patents
    18
  • GoodIP Patent Rank
    127,416
About

LABORATORIO RAAM DE SAHUAYO S A DE C V has a total of 18 patent applications. Its first patent ever was published in 2013. It filed its patents most often in Mexico, Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals are AEQUUS PHARMACEUTICALS INC, GILA THERAPEUTICS INC and MC2 THERAPEUTICS LTD.

Patent filings in countries

World map showing LABORATORIO RAAM DE SAHUAYO S A DE C Vs patent filings in countries
# Country Total Patents
#1 Mexico 9
#2 Canada 3
#3 EPO (European Patent Office) 3
#4 United States 3

Patent filings per year

Chart showing LABORATORIO RAAM DE SAHUAYO S A DE C Vs patent filings per year from 1900 to 2020

Focus industries

# Industry
#1 Pharmaceuticals

Focus technologies

Top inventors

# Name Total Patents
#1 Amezcua Amezcua Federico 9
#2 Federico Amezcua Amezcua 7
#3 Covarrubias Pinedo Amador 6
#4 Miguel Ángel Gómez Lim 4
#5 Laura Uribe Campero 4
#6 Félix Martín Gutiérrez López 4
#7 María Isabel Saad Villegas 4
#8 Amador Covarrubias Pinedo 2
#9 Jose Manuel Francisco Lara Ochoa 2

Latest patents

Publication Filing date Title
MX2015004542A Improved human coagulation factor ix produced in plants.
MX2015004543A Improved human coagulation factor xi produced in plants.
MX2015004541A Improved human coagulation factor viii produced in plants.
MX2015004540A Improved human coagulation factor vii produced in plants.
CA2946154A1 Three-phase system for modified release of a non-steroidal antiinflammatory
MX2013008996A Novel pharmaceutical system of biphasic delivery for treating pain and inflammation.
MX2013008994A Stable solid composition of immunosuppressants.
MX2013008992A Pharmaceutical composition with anti-inflammatory agents and production process thereof.
MX2013008152A Pharmaceutical compositions from salt s(+)-ibuprofen with l-arginine and salt s(-)-naproxen with l-arginine.
MX2013005378A Salts of the active enantiomer of s-ketorolac.